Effects on thrombocytic hemostasis of a new derivate indolinone
Bykov V. V., Serebrov V., Udut V. V., Udut E. V., Fisenko V. P.
Bangladesh Journal of Medical Science
Vol.18, Issue3, P. 574-576
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.3329/bjms.v18i3.41628
Аннотация:
Objective. Specific activity of an antiplatelet drug of indolinone series (codenamed DI) was studied in vitro in a model of ADP-induced platelet aggregation in vitro and in vivo in a model of streptozotocininduced diabetes mellitus in rats. Material and Methods. Acetylsalicylic acid and dipyridamole were used as reference drugs. In vitro tests have demonstrated that DI exhibits antiplatelet activity in a wide range of concentrations (0,75×10-6 – 1.5×10-5 М, р<0,05), being comparable to acetylsalicylic acid and dipyridamole. In vivo tests have demonstrated dose-dependent antiplatelet activity of DI in doses of 2,5 – 20 mg/kg (21-14 [%]). Results and Discussion.Increasing the dose of DI above 10 mg/kg doesn’t increase its antiplatelet activity. After multiple oral administration to rats with streptozotocin-induced diabetes mellitus in 10 mg/kg dose, DI has exhibited antiplatelet activity, reducing the platelet aggregation rate to that of the control group (р<0,05).Conclusion. Thus, DI isap
Ключевые слова:
Acetylsalicylic acid; Antiplatelet; Dipyridamole; Indolinone derivative; Platelet aggregation
acetylsalicylic acid; antithrombocytic agent; dipyridamole; indole derivative; oxindole; streptozocin; unclassified drug; [2 [(5RS) 5 (hydroxymethyl) 3 methyl 1,3 oxazolidine 2 yliden] 2 cyanoethylidene] 1H indol 3(2H) one); animal experiment; antiplatelet activity; Article; controlled study; diabetes mellitus; glucose blood level; hemostasis; in vitro study; in vivo study; male; nonhuman; peripheral occlusive artery disease; platelet count; rat; single drug dose; streptozotocin-induced diabetes mellitus; thrombocyte aggregation; thrombocyte poor plasma
Язык текста: Английский
ISSN: 2223-4721
Bykov V. V.
Serebrov V.
Udut V. V.
Udut E. V.
Fisenko V. P. Vladimir Petrovich 1946-
Бyков В. В.
Серебров В.
Удут В. В.
Удут Е. В.
Фисенко В. П. Владимир Петрович 1946-
Effects on thrombocytic hemostasis of a new derivate indolinone
Текст визуальный непосредственный
Bangladesh Journal of Medical Science
Vol.18, Issue3 P. 574-576
2019
Статья
Acetylsalicylic acid Antiplatelet Dipyridamole Indolinone derivative Platelet aggregation
acetylsalicylic acid antithrombocytic agent dipyridamole indole derivative oxindole streptozocin unclassified drug [2 [(5RS) 5 (hydroxymethyl) 3 methyl 1,3 oxazolidine 2 yliden] 2 cyanoethylidene] 1H indol 3(2H) one) animal experiment antiplatelet activity Article controlled study diabetes mellitus glucose blood level hemostasis in vitro study in vivo study male nonhuman peripheral occlusive artery disease platelet count rat single drug dose streptozotocin-induced diabetes mellitus thrombocyte aggregation thrombocyte poor plasma
Objective. Specific activity of an antiplatelet drug of indolinone series (codenamed DI) was studied in vitro in a model of ADP-induced platelet aggregation in vitro and in vivo in a model of streptozotocininduced diabetes mellitus in rats. Material and Methods. Acetylsalicylic acid and dipyridamole were used as reference drugs. In vitro tests have demonstrated that DI exhibits antiplatelet activity in a wide range of concentrations (0,75×10-6 – 1.5×10-5 М, р<0,05), being comparable to acetylsalicylic acid and dipyridamole. In vivo tests have demonstrated dose-dependent antiplatelet activity of DI in doses of 2,5 – 20 mg/kg (21-14 [%]). Results and Discussion.Increasing the dose of DI above 10 mg/kg doesn’t increase its antiplatelet activity. After multiple oral administration to rats with streptozotocin-induced diabetes mellitus in 10 mg/kg dose, DI has exhibited antiplatelet activity, reducing the platelet aggregation rate to that of the control group (р<0,05).Conclusion. Thus, DI isap